Immune Checkpoint Inhibitors Market to Reach $29,758.1 Million by 2035

Immune Checkpoint Inhibitors market was valued at $6,665.0 million in 2025 and is expected to reach $29,758.1 million by 2035, registering a CAGR of 16.2% during the forecast period from 2026 to 2035. The rising burden of cancer in the US continues to strengthen the demand outlook for immune checkpoint inhibitors, particularly across tumor types where immunotherapy has become a standard treatment approach. Increasing diagnosis rates across lung, breast, colorectal, bladder, melanoma, and kidney cancers are expanding the eligible patient population for PD-1, PD-L1, and CTLA-4 inhibitors, encouraging healthcare providers to integrate these therapies earlier within oncology care pathways. Government statistics highlight a substantial clinical load on oncology systems, reinforcing the need for advanced treatments that offer durable responses and improved survival outcomes. As pharmaceutical companies continue to expand label approvals and combination therapy strategies, the growing incidence and mortality burden directly support long-term market growth and sustained adoption of immune checkpoint inhibitors across major cancer indications.

Browse the full report description of “Immune Checkpoint Inhibitors Market Size, Share and Trends Analysis Report, By Drug Class (Programmed Death Receptor-1 Inhibitors (PD-1), Programmed Death-Ligand 1 Inhibitors (PD-L1), CTL-4 Checkpoint Inhibitor, Indoleamine-2,3-dioxygenase (IDO) Inhibitors, and Lymphocyte-Activation Gene 3 Inhibitors), By Application (Lung Cancer, Head & Neck Cancer, Blood Cancer, Bladder Cancer, Skin Cancer, Colorectal Cancer, Renal/Kidney Cancer, Breast Cancer, and Others) Forecast Period, (2026-2035)” at https://www.omrglobal.com/industry-reports/immune-checkpoint-inhibitors-market

• In 2025, an estimated 2,041,910 new cancer cases and 618,120 cancer-related deaths are expected in the US, indicating a large treatment population that drives demand for innovative immunotherapies.
• Major cancers such as breast, lung, colorectal, melanoma, bladder, and kidney cancer remain among the most frequently diagnosed, aligning closely with key application segments of immune checkpoint inhibitors.
• Prostate, lung, and colorectal cancers account for around 48% of new diagnoses in men, while breast, lung, and colorectal cancers represent nearly 51% of new cases in women, supporting sustained clinical adoption of checkpoint inhibitors.
• The annual cancer incidence rate stands at approximately 445.8 cases per 100,000 people, reflecting a consistent rise in oncology treatment requirements and long-term therapy demand.
• Cancer mortality is estimated at 145.4 deaths per 100,000 individuals annually, emphasizing the need for advanced therapies that can improve survival outcomes and reduce disease progression.

Major Leaders Transforming the Immune Checkpoint Inhibitors Market

The key players in the immune checkpoint inhibitors market include Merck & Co., Inc., Bristol Myers Squibb, F. Hoffmann-La Roche Ltd., AstraZeneca plc, and Pfizer Inc., among others. These companies are driving innovation through expanded immuno-oncology pipelines, combination therapy development, and continuous clinical research aimed at improving efficacy across major cancer indications. Ongoing investments in novel checkpoint targets and precision treatment approaches are strengthening their market positions and supporting sustained industry growth.

• In October 2025, Takeda entered a global licensing and collaboration agreement with Innovent Biologics to develop and commercialize next-generation oncology medicines, including investigational immunotherapy candidates for solid tumors, strengthening pipeline expansion and global commercialization capabilities.
• In January 2025, ImmunityBio announced a collaboration with BeiGene to advance a Phase 3 clinical trial combining ANKTIVA with a PD-1 checkpoint inhibitor for non-small cell lung cancer, reflecting growing industry focus on combination immunotherapy strategies.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Drug Class
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - Merck & Co., Inc., Bristol Myers Squibb, F. Hoffmann-La Roche Ltd., AstraZeneca plc, Pfizer Inc., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Immune Checkpoint Inhibitors Market Report Segment

By Drug Class

• Programmed Death Receptor-1 Inhibitors (PD-1)
• Programmed Death-Ligand 1 Inhibitors (PD-L1)
• CTL-4 Checkpoint Inhibitor
• Indoleamine-2,3-dioxygenase (IDO) Inhibitors
• Lymphocyte-Activation Gene 3 Inhibitors

By Application

• Lung Cancer
• Head and Neck Cancer
• Blood Cancer
• Bladder Cancer
• Skin Cancer
• Colorectal Cancer
• Renal/Kidney Cancer
• Breast Cancer
• Others

Global Immune Checkpoint Inhibitors Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/immune-checkpoint-inhibitors-market